Tuberculosis remains one of the deadliest infectious diseases globally, with over 10 million new cases each year. Diagnosis is further complicated by non-tuberculous mycobacteria (NTM), which cause clinically similar pulmonary infections but require entirely different treatment strategies. Traditional smear microscopy and culture methods are time-consuming and cannot reliably differentiate MTBC from NTM, delaying critical treatment decisions and increasing the risk of disease spread.
The MTB-NTM Multiplex Real-Time PCR Kit from Genes2Me enables simultaneous, qualitative detection and differentiation of MTBC and NTM in a single assay. It works directly from a broad range of respiratory and extra-pulmonary samples, delivering rapid, accurate results that empower clinicians to initiate the right treatment without delay.
Genes2Me is a CE Marked molecular diagnostics company trusted by clinical laboratories across global markets. The MTB-NTM Multiplex Real-Time PCR Kit meets European conformity standards for in vitro diagnostic devices, validated to international benchmarks for accuracy, reliability, and safety.
The MTB-NTM kit uses TaqMan chemistry-based multiplex real-time PCR to simultaneously target and differentiate two mycobacterial groups. The mpb64 gene is targeted for MTBC detection in the Texas Red channel, while a conserved region of the 16S rRNA gene is targeted for NTM detection in the HEX channel. RNaseP serves as an internal control monitored in the Cy5 channel, validating extraction and amplification efficiency in every run. Positive and no-template controls are included to ensure assay reliability across all workflows.
MTBC and NTM infections present with near-identical symptoms, yet their treatment protocols differ significantly. Misidentification leads to inappropriate therapy, treatment delays, and continued disease transmission. A multiplex approach with three independent detection channels identifies both pathogen groups and validates the run simultaneously, reducing diagnostic turnaround from days to hours and ensuring clinicians have the information they need to act decisively.
A single multiplex assay differentiates Mycobacterium tuberculosis complex from non-tuberculous mycobacteria, eliminating the need for separate tests and accelerating clinical decision-making.
MTBC is monitored via Texas Red, NTM via HEX, and the RNaseP internal control via Cy5, enabling precise, independent identification of each target in every run.
Targets the mpb64 gene for MTBC and the 16S rRNA gene for NTM, ensuring highly specific identification and reliable differentiation from clinically similar pathogens.
Accepts sputum, tracheal aspirate, throat swab, nasopharyngeal and oropharyngeal swabs, BAL, and other extra-pulmonary samples, offering flexibility across clinical collection protocols.
Both controls are supplied in every kit, ensuring assay reliability and guarding against contamination or procedural errors.
Pre-formulated reagents and a simplified assay protocol reduce handling time, minimise procedural errors, and support consistent results across runs.
| Commercial Name | Old Cat No. | New Cat No. | Pack Size |
|---|---|---|---|
| MTB-NTM Multiplex Real-Time PCR Kit | G610015-1 | 50 Tests |
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
© 2025 Genes2me. All rights reserved.
